ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HEME Healthmed Services Ltd (PK)

0.0006
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Healthmed Services Ltd (PK) USOTC:HEME OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0006 0.0005 0.0016 0.00 01:00:00

HealthMed Services, Ltd. Completes Merger With Subsidiary

22/04/2011 12:50am

Marketwired


Healthmed Services (PK) (USOTC:HEME)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Healthmed Services (PK) Charts.

HealthMed Services, Ltd. (PINKSHEETS: HEME) is pleased to announce that its subsidiary, Health Emergent Technologies, Inc., was merged with and into HealthMed Services, Ltd. on April 7, 2011. It was further disclosed that the new officers and directors of the Company are Henry J. Smith, who serves as a Director, President and Secretary, and Richard E. Floegel, who serves as a Director, Vice President and Chief Financial Officer.

The merger has no material effect on current shareholders and consolidates the Company's proprietary rights to the Donor Organ Transport System invented by Henry J. Smith and assigned to the Company. This Donor Organ Transport System has been adopted to be the key component of a new and improved business model being pursued by the Company's new management. The Company's website and OTC Markets, Inc. disclosure information are undergoing updates to reflect and inform the public of these significant changes.

About HealthMed Services, Ltd.

The Company has acquired the rights from Dr. Henry J. Smith to an improved Donor Organ Transport System (Patent Pending). By reconditioning the donor organ such as the heart, kidney or liver and extending the period of time for transport, it will be possible to improve the success rates of transplants. Also, by having a device that can maintain the organ for an extended period in vitro, it will be possible to test drugs on isolated organs in vitro before starting clinical trials on patients. The Company has made significant progress in its research program and has a working model of a portable organ transport device. Dr. Smith has completed the initial research studies showing that isolated donor organs could be kept alive for an extended period of time using the organ transport system developed. Research has indicated this device to be what is needed and desired for the practice of medicine, and it represents strong possibility to be the foundation for an enterprise highly profitable to the Company and its shareholders.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with cleaning fluid and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report, quarterly reports or current reports filed from time-to-time with OTC Markets, Inc.

Contact: Richard E. Floegel (619) 248-6868

1 Year Healthmed Services (PK) Chart

1 Year Healthmed Services (PK) Chart

1 Month Healthmed Services (PK) Chart

1 Month Healthmed Services (PK) Chart

Your Recent History

Delayed Upgrade Clock